Patch D, Sabin C A, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs A K
Department of Liver Transplantation and Hepatobiliary Medicine, University Department of Surgery, Royal Free Hospital Hampstead NHS Trust, London, UK.
Gastroenterology. 2002 Oct;123(4):1013-9. doi: 10.1053/gast.2002.35955.
BACKGROUND & AIMS: Patients who have had one variceal bleed are at high risk of rebleeding. Since its introduction, endoscopic variceal banding has been shown to be superior to needle sclerotherapy. Banding has not been compared with hepatic venous pressure-guided medical therapy (beta-blockers and nitrates).
One hundred two patients with cirrhosis and a recent esophageal variceal bleed were randomized to either endoscopic banding (51 patients) or medical therapy (51 patients). The hepatic venous pressure gradient was measured in all patients at baseline, at 3 months (drug therapy arm), and at yearly intervals (all patients). Primary end points were death or rebleeding.
The 2 groups were well matched. Fifty-one percent were Pughs C, with a median Pughs score of 9.5. Nineteen patients rebled in the drug arm (median time, 24 days) and 27 patients in the banding arm (median time, 24 days). At 1 year, 43.7% of patients had bled in the drug arm compared with 53.8% in the banding arm (P = 0.25). Thirty-two percent of patients on medical therapy had died at 1 year, 22.5% on banding (P = 0.97).
In the prevention of variceal rebleeding, beta-blockers +/- nitrates are as effective as endoscopic banding.
曾发生过一次静脉曲张出血的患者再次出血风险很高。自内镜下静脉曲张套扎术应用以来,已证明其优于针状硬化疗法。但套扎术尚未与肝静脉压力引导下的药物治疗(β受体阻滞剂和硝酸盐)进行比较。
102例肝硬化且近期有食管静脉曲张出血的患者被随机分为内镜套扎组(51例患者)或药物治疗组(51例患者)。在基线、3个月时(药物治疗组)以及每年(所有患者)对所有患者测量肝静脉压力梯度。主要终点是死亡或再次出血。
两组匹配良好。51%为Pughs C级,Pughs评分中位数为9.5。药物治疗组有19例患者再次出血(中位时间24天),套扎组有27例患者再次出血(中位时间24天)。1年后,药物治疗组43.7%的患者出血,套扎组为53.8%(P = 0.25)。药物治疗组1年时32%的患者死亡,套扎组为22.5%(P = 0.97)。
在预防静脉曲张再出血方面,β受体阻滞剂±硝酸盐与内镜套扎术效果相当。